


AMENDMENTS OF THE CLAIMS

The following **Listing of Claims**, in which deleted text appears as ~~struck through~~ or within bolded double brackets (e.g., **[[text]]**), and inserted text appears as underlined, will replace all prior versions and listings of claims in the application. Text within single brackets stems for the original claims and should not be deleted.

Listing of Claims

Claim 1 (currently amended): A compound ~~of the~~ according to structural Formula I



wherein:

Q_a is phenyl, and Q_a may optionally bear 1 or 2 substituents R^a and R^b are each, independently of one another, selected from the group consisting of hydrogen, hydroxy, halogeno, trifluoromethyl, cyano, amino, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylamino, di-[(1-6C)alkyl]amino and (1-6C)alkoxycarbonyl;

R₁ and R₂ are each independently of one another selected from the group consisting of hydrogen, (1-6C)alkyl, (2-6C)alkenyl and (2-6C)alkynyl; and

Q_b is pyridyl, and Q_b may optionally bear 1 or 2 substituents R^c and R^d are each independently of one another, selected from the group consisting of hydrogen, hydroxy, halogeno, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-6C)alkyl, (1-6C)alkoxy, (3-6C)cycloalkoxy, (3-6C)cycloalkyl-(1-6C)alkoxy, carboxy, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbonyl, N,N-di-[(1-6C)alkyl]carbonyl, (2-6C)alkanoyl, amino, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, aminosulphonyl, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl and (3-6C)cycloalkylsulphonyl;

and wherein any of the R^a , R^b , R^c and/or R^d substituents on Q_a or Q_b defined hereinbefore which ~~comprise a CH_2 group attached to 2 carbon atoms or a CH_3 group attached to a carbon atom may optionally bear on each said CH_2 or CH_3 group that include a methylene or methyl group may optionally be substituted on said methylene or methyl group with one or more substituents independently selected from the group consisting of hydroxy, cyano, amino, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylamino and di-[(1-6C)alkyl]amino;~~
or a pharmaceutically-acceptable salt thereof.

Claim 2 (currently amended): A compound of the Formula I according to ~~claim 1~~ wherein Q_a ~~may optionally bear 1 or 2 substituents~~ The compound or pharmaceutically acceptable salt of claim 1 in which R^a and R^b are each, independently of one another, selected from the group consisting of hydrogen, halogeno, (1-6C)alkyl and (1-6C)alkoxy; ~~or a pharmaceutically-acceptable salt thereof.~~

Claim 3 (currently amended): A compound of the Formula I according to ~~claim 1~~ wherein Q_a ~~may optionally bear 1 or 2 substituents~~ The compound or pharmaceutically acceptable salt of claim 1 in which the R^c and R^d are each, independently of one another, selected from the group consisting of hydrogen, hydroxy, halogeno, (1-6C)alkyl and (1-6C)alkoxy; ~~or a pharmaceutically-acceptable salt thereof.~~

Claims 4-6 (previously cancelled).

2 **Claim 7** (currently amended): A compound of the Formula I according to The compound or pharmaceutically acceptable salt of claim 1 or claim 2 wherein R_1 and R_2 are each independently of one another selected from the group consisting of hydrogen and (1-6C)alkyl; ~~or a pharmaceutically-acceptable salt thereof.~~

Claim 8 (previously cancelled).

Claim 9 (currently amended): A compound ~~of the Formula I according to claim 1~~ selected from the group consisting of:

N-cyclopropyl-4-methyl-3-{{4-(pyridine-2-ylmethoxy)benzoyl}amino}benzamide;

N-cyclopropyl-4-methyl-3-{{4-(pyridine-3-ylmethoxy)benzoyl}amino}benzamide;

N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3-methoxy-4-(pyridin-2-ylmethoxy)benzamide;

N-cyclopropyl-4-methyl-3-{{3-methyl-4-(pyridin-2-ylmethoxy) benzoyl}amino}benzamide;

N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide;
N-cyclopropyl-4-methyl-3-{[3-(pyridin-2-ylmethoxy)benzoyl]amino}benzamide;
3-chloro-*N*-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-4-(pyridin-2-ylmethoxy)benzamide;
N-cyclopropyl-3-({4-[(4-methoxypyridin-2-yl)methoxy]benzoyl}amino)-4-methylbenzamide;
N-cyclopropyl-4-methyl-3-{[4-(1-pyridin-2-ylethoxy)benzoyl]amino}benzamide;
N-cyclopropyl-3-({3-[(4-methoxypyridin-2-yl)methoxy]benzoyl}amino)-4-methylbenzamide;
N-cyclopropyl-3-[(4-{[5-(hydroxymethyl)pyridine-2-yl]methoxy}benzoyl)amino]-4-methylbenzamide;
N-cyclopropyl-3-[(4-{[5-(1-hydroxy-1-methylethyl)pyridin-2-yl]methoxy}benzoyl)amino]-4-methylbenzamide;
N-cyclopropyl-3-{[4-({5-[(isopropylamino)methyl]pyridin-2-yl)methoxy}benzoyl]amino}-4-methylbenzamide;
N-cyclopropyl-3-{[4-({5-[(dimethylamino)methyl]pyridin-2-yl}methoxy)benzoyl]amino}-4-methylbenzamide;
methyl 6-({4-[(5-[(cyclopropylamino)carbonyl]-2-methylphenyl)amino)carbonyl]phenoxy}methyl) nicotinate;
N-cyclopropyl-3-{[4-({5-[2-(dimethylamino)ethoxy]pyridin-2-yl}methoxy)benzoyl] amino}-4-methylbenzamide;
N-cyclopropyl-3-({4-[(5-hydroxypyridin-2-yl)methoxy]benzoyl}amino)-4-methylbenzamide;
methyl 6-({4-[(5-[(cyclopropylamino)carbonyl]-2-methylphenyl)amino)carbonyl]phenoxy}methyl) pyridine-2-carboxylate;
N-cyclopropyl-3-[(4-{[6-(hydroxymethyl)pyridin-2-yl]methoxy}benzoyl)amino]-4-methylbenzamide;
N-cyclopropyl-3[(4-{[6-(1-hydroxy-1-methylethyl)pyridin-2-yl]methoxy}benzoyl)amino]-4-methylbenzamide;
N-cyclopropyl-3-({4-[(6-{[2-(diethylamino)ethoxy]methyl}pyridin-2-yl)methoxy]benzoyl}amino)-4-methylbenzamide;
N-cyclopropyl-3-({4-[(6-{[2-(dimethylamino)ethoxy]methyl}pyridin-2-yl)methoxy]benzoyl}amino)-4-methylbenzamide;
3-({4-[(6-bromopyridin-2-yl)methoxy]benzoyl}amino)-*N*-cyclopropyl-4-methylbenzamide;

N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3,5-difluoro-4-(pyridin-2-ylmethoxy)benzamide;
N-cyclopropyl-4-methyl-3-({4-[(6-methylpyridin-2-yl)methoxy]benzoyl}amino)benzamide;
N-cyclopropyl-4-methyl-3-({4-[(3-methylpyridin-2-yl)methoxy]benzoyl}amino)benzamide;
N-cyclopropyl-3-{[4-({6-[(2-methoxyethyl)amino]pyridin-2-yl}methoxy)benzoyl]amino}-4-methylbenzamide; and

N-cyclopropyl-3-({4-[(6-{[2-(dimethylamino)ethyl]amino}pyridin-2-yl)methoxy]benzoyl}amino)-4-methylbenzamide;

or a and pharmaceutically-acceptable salt salts thereof.

Claim 10 (cancelled herein).

Claim 11 (currently amended): A pharmaceutical composition ~~which comprises a compound of the Formula I as claimed in any one of claims 1, 2 and 9, or a pharmaceutically-acceptable salt thereof, in association with~~ comprising a compound or pharmaceutically acceptable salt according to any one of claims 1, 2, 3, 7, 9, 17, 18, 19, 20, 21 and 22 and a pharmaceutically-acceptable diluent or carrier.

Claims 12-15 (previously cancelled).

Claim 16 (withdrawn and currently amended): A method for ~~the treatment of rheumatoid arthritis, osteoarthritis, asthma, chronic obstructive pulmonary disease, inflammatory bowel disease, multiple sclerosis, AIDS, septic shock, congestive heart failure, ischaemic heart disease or psoriasis in a warm blooded animal in need thereof~~ treating arthritis comprising administering to ~~said animal a subject suffering from arthritis~~ an effective amount of a compound ~~of the Formula I as claimed in any one of claims 1, 2 and 9, or a pharmaceutically-acceptable salt thereof~~ or pharmaceutically acceptable salt according to any one of claims 1, 2, 3, 7, 9, 17, 18, 19, 20, 21 and 22.

Claim 17 (currently amended): ~~The compound~~ *N*-cyclopropyl-4-methyl-3-{[4-(pyridin-2-ylmethoxy)benzoyl]amino}benzamide, or a pharmaceutically-acceptable salt thereof.

Claim 18 (currently amended): ~~The compound~~ *N*-cyclopropyl-4-methyl-3-{[4-(pyridin-3-ylmethoxy)benzoyl]amino}benzamide, or a pharmaceutically-acceptable salt thereof.

Claim 19 (currently amended): ~~The compound~~ *N*-{5-(cyclopropylamino)carbonyl]-2-methylphenyl}-3-methoxy-4-(pyridin-2-ylmethoxy)benzamide, or a pharmaceutically-acceptable salt thereof.

Claim 20 (currently amended): ~~The compound~~ *N*-cyclopropyl-4-methyl-3-{[3-methyl-4-(pyridin-2-ylmethoxy)benzoyl]amino}benzamide, or a pharmaceutically-acceptable salt thereof.

Claim 21 (currently amended): ~~The compound~~ *N*-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide, or a pharmaceutically-acceptable salt thereof.

Claim 22 (currently amended): ~~The compound~~ 3-chloro-*N*-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-4-(pyridin-2-ylmethoxy)benzamide, or a pharmaceutically-acceptable salt thereof.

Claim 23 (new): A method of treating arthritis comprising administering to a subject in need there of an effective amount of a pharmaceutical composition according to **claim 16**.

Claim 24 (new): A method of inhibiting a p38 kinase, comprising contacting a p38 kinase with a compound or pharmaceutically acceptable salt according to **any one of claims 1, 2, 3, 7, 9, 17, 18, 19, 20, 21 and 22**.